Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression Data from pancreatic cancer cell lines and orthotopic tumors grown with and without MEK inhibitor

ABSTRACT: This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

ORGANISM(S): Homo sapiens

SUBMITTER: Stephan Gysin 

PROVIDER: E-GEOD-45765 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.

Gysin Stephan S   Paquette Jesse J   McMahon Martin M  

Molecular cancer research : MCR 20120725 12

Mutationally activated KRAS, detected in approximately 90% of pancreatic ductal adenocarcinomas (PDA), has proven an intractable pharmacologic target to date. Consequently, efforts to treat KRAS-mutated cancers are focused on targeting RAS-regulated signaling pathways. In mouse models, expression of BRAF(V600E) combined with dominant-negative TP53 elicits PDA, and pharmacologic blockade of mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibits proliferation of human PDA-d  ...[more]